Drug Application (NDA) for etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PVST). Etripamil is an
Apomorphine, a non-ergoline dopamine agonist, is believed to siteName MPR siteURL siteID 7 Etripamil Nasal Spray
The trial, in which patients are randomized 1:1 to receive either 70 mg of etripamil or placebo, is designed to assess the safety and efficacy of etripamil nasal spray to reduce elevated
Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to
Etripamil nasal spray is being developed for self-administration by patients for the treatment of paroxysmal supraventricular tachycardia.
by BS Stambler 2024 Cited by 55Reductions in blood pressure occurred predominantly in the highest etripamil dose. CONCLUSIONS Etripamil nasal spray rapidly terminated induced SVT with a high
A nasal spray containing etripamil, an investigational calcium channel blocker, significantly benefits patients with paroxysmal supraventricular
Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia (NODE-303 Etripamil Clinical Research in PSVT). Principal Investigator: Marco
Multi-Centre, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia.
Comments